On June 1 Avacta reported updated Phase 1a/1b data for faridoxorubicin (AVA6000), a pre|CISION-enabled, FAP-activated doxorubicin peptide-drug conjugate that releases its payload inside the tumor microenvironment. At the recommended expansion dose of 310 mg/m², nearly three times conventional doxorubicin's 75 mg/m² maximum tolerated dose, toxicity stayed below historical doxorubicin rates, and the salivary gland cancer cohort held multiple confirmed responses: four partial and nine minor responses among 38 evaluable patients.
Avacta's AVA6000 — a fibroblast activation protein (FAP)-activated peptide-drug conjugate releasing doxorubicin selectively in the tumor microenvironment — released Phase 1a/1b data at ASCO 2026 in salivary gland cancers. Of 30 patients in the Phase 1b cohort treated at 250 mg/m² and above, two experienced confirmed partial responses (>30% tumor shrinkage) and seven experienced minor responses (10-30% shrinkage). The combined Phase 1a + 1b disease control rate reached 90%. Phase 1a data in 11 patients at the same dose range showed 1 confirmed partial response, 4 minor responses, 1 progression, and 5 stable disease — a 91% disease control rate. The favorable safety profile continued versus conventional doxorubicin, with no severe cardiac toxicity events. The data anchors Avacta's planned Phase 2/3 expansion in adenoid cystic carcinoma — the most common salivary gland cancer subtype, with no FDA-approved systemic therapy.
Avacta Therapeutics's AVA6000, a fibroblast activation protein (FAP)-activated peptide-drug conjugate releasing doxorubicin selectively in the tumor microenvironment, will be presented at ASCO 2026 (Chicago, May 29-June 2) covering Phase Ia/Ib data in FAP-positive solid tumors with activity against salivary gland cancers — a rare cancer subset with no approved targeted therapies. The pre|CISION platform attaches a peptide tetrazolyl moiety that is cleaved by FAP, an enzyme overexpressed in cancer-associated fibroblasts and selectively present in the tumor stroma, allowing systemic dosing without the cardiotoxicity that limits free doxorubicin.